Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Yuzhi Pang"'
Autor:
Feifei Xie, Shuzhen Luo, Dongbing Liu, Xiaojing Lu, Ming Wang, Xiaoxiao Liu, Fujian Jia, Yuzhi Pang, Yanying Shen, Chunling Zeng, Xinli Ma, Daoqiang Tang, Lin Tu, Linxi Yang, Yumei Cheng, Yuxiang Luo, Fanfan Xie, Hao Hou, Tao Huang, Bo Ni, Chun Zhuang, Wenyi Zhao, Ke Li, Xufen Zheng, Wenbo Bi, Xiaona Jia, Yi He, Simin Wang, Hui Cao, Kui Wu, Yuexiang Wang
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract Gastrointestinal stromal tumor (GISTs) are clinically heterogenous exhibiting varying degrees of disease aggressiveness in individual patients. We comprehensively describe the genomic and transcriptomic landscape of a cohort of 117 GISTs inc
Externí odkaz:
https://doaj.org/article/d6bf3660228748eb9ad388fe35262001
Autor:
Simin Wang, Yangjie Xiong, Yuxiang Luo, Yanying Shen, Fengrui Zhang, Haoqi Lan, Yuzhi Pang, Xiaofang Wang, Xiaoqi Li, Xufen Zheng, Xiaojing Lu, Xiaoxiao Liu, Yumei Cheng, Tanwen Wu, Yue Dong, Yuan Lu, Jiujie Cui, Xiaona Jia, Sheng Yang, Liwei Wang, Yuexiang Wang
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 5, Pp 1115-1142 (2024)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with an overall 5-year survival rate of
Externí odkaz:
https://doaj.org/article/abb29ed6ca354abcb56f3459b63f402e
Autor:
Luyao Guan, Zhang Li, Feifei Xie, Yuzhi Pang, Chenyun Zhang, Haosha Tang, Hao Zhang, Chun Chen, Yaying Zhan, Ting Zhao, Hongyuan Jiang, Xiaona Jia, Yuexiang Wang, Yuan Lu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-11 (2020)
Abstract Background Epithelial ovarian cancer (EOC) is a highly lethal malignancy. Improvement in genetic characterization of EOC patients is required to propose new potential targets, since surgical resection coupled to chemotherapy, presents severa
Externí odkaz:
https://doaj.org/article/55059d605a2a411d867cf54ae4d6c746
Autor:
Yuexiang Wang, Jen-Chieh Lee, Xiaona Jia, Yanying Shen, Lin Tu, Xiaoxiao Liu, Hui Cao, Yuzhi Pang, Xiaojing Lu
Supplementary Tables 1-5. Supplementary Table S1. Clinicopathologic classification and CDK1 expression for the discovery GIST cohort (n=43). Supplementary Table S2: List of all 14280 genes expressed in GIST. Supplementary Table S3: List of 568 genes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57830f55c5419f9919c8b2e72c08a5cf
https://doi.org/10.1158/0008-5472.22430641
https://doi.org/10.1158/0008-5472.22430641
Autor:
Yuexiang Wang, Jen-Chieh Lee, Xiaona Jia, Yanying Shen, Lin Tu, Xiaoxiao Liu, Hui Cao, Yuzhi Pang, Xiaojing Lu
Oncogenic KIT or PDGFRA receptor tyrosine kinase mutations are compelling therapeutic targets in gastrointestinal stromal tumor (GIST), and treatment with the KIT/PDGFRA inhibitor imatinib is the standard of care for patients with advanced GIST. Poly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::635ec293ef8717401f76b247be9a1a8d
https://doi.org/10.1158/0008-5472.c.6513673.v1
https://doi.org/10.1158/0008-5472.c.6513673.v1
Autor:
Xiaona Jia, Linhui Wang, Yuzhi Pang, Tao Huang, Meijun Zhu, Xufen Zheng, Feifei Xie, Yuexiang Wang, Xiaojing Lu, Yanying Shen, Hui Cao, Ke Li, Jonathan A. Fletcher, Zhang Li, Chunmeng Wang, Xiaoxiao Liu, Simin Wang, Yi He
Publikováno v:
Proceedings of the National Academy of Sciences. 116:22746-22753
Gastrointestinal stromal tumors (GISTs) are the most common human sarcoma and are initiated by activating mutations in the KIT or PDGFRA receptor tyrosine kinases. Chromosome 22q deletions are well-recognized frequent abnormalities in GISTs, occurrin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::287811390d15df0a84225b18aba7f0c9
https://doi.org/10.1073/pnas.1914542116
https://doi.org/10.1073/pnas.1914542116
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer
Autor:
Zhizhan Gu, Yichuan Xiao, Kenan Huang, Chunling Zeng, Zhang Li, Xiaojing Lu, Wenbo Bi, Miaoying Zhang, Yanying Shen, Feifei Xie, Xiaoxiao Liu, Yi He, Rongqiang Wei, Ke Li, Xufen Zheng, Zihao Chen, Simin Wang, Yuan-Sheng Zang, Hua Tang, Qingchen Zhu, Xiaoyang Zhang, Yuxiang Luo, Jonathan A. Fletcher, Tao Huang, Yuexiang Wang, Xiaona Jia, Yuzhi Pang
Publikováno v:
The Journal of Experimental Medicine
Recurrent inactivated mutations in central precocious puberty-associated gene MKRN3 lead to lung cancer proliferation and progression through PABPC1 ubiquitination–mediated global protein synthesis. MKRN3 is a bona fide tumor suppressor, and MKRN3-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630f663ede66349491bf18247fc32295
https://pubmed.ncbi.nlm.nih.gov/34143182
https://pubmed.ncbi.nlm.nih.gov/34143182
Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors
Autor:
Yuexiang Wang, Lin Tu, Xiaojing Lu, Jen-Chieh Lee, Yuzhi Pang, Xiaona Jia, Yanying Shen, Hui Cao, Xiaoxiao Liu
Publikováno v:
Cancer research. 81(9)
Oncogenic KIT or PDGFRA receptor tyrosine kinase mutations are compelling therapeutic targets in gastrointestinal stromal tumor (GIST), and treatment with the KIT/PDGFRA inhibitor imatinib is the standard of care for patients with advanced GIST. Poly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0556807ed9f78bf499b2dc5edc3b96f0
https://pubmed.ncbi.nlm.nih.gov/33727226
https://pubmed.ncbi.nlm.nih.gov/33727226
Autor:
Feifei Xie, Chunling Zeng, Lili Duan, Yuexiang Wang, Xiaona Jia, Yuzhi Pang, Zhang Li, Xiaojing Lu, Li Zhu
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 23(5)
The majority of GISTs express mutationally activated KIT. Imatinib and sunitinib are approved KIT-inhibiting therapies. Their efficacy is usually hampered by the acquired multiple secondary drug-resistance KIT mutations. The most problematic resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8b8607332a06215972c2b370fee7265
https://pubmed.ncbi.nlm.nih.gov/32291709
https://pubmed.ncbi.nlm.nih.gov/32291709
Autor:
Luyao Guan, Li, Zhang, Feifei Xie, Yuzhi Pang, Chenyun Zhang, Haosha Tang, Zhang, Hao, Chen, Chun, Yaying Zhan, Zhao, Ting, Hongyuan Jiang, Xiaona Jia, Yuexiang Wang, Lu, Yuan
Additional file 1: Supplementary Figure 1. PTKs-encoding genes. Supplementary Figure 2. Endogenous RET expression in human ovarian cancer cells. (A) The RNA-seq data from epithelial ovary carcinoma patients from the TCGA program (TCGA Pan Can Atlas s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66807978864ae6c4c763dd2da429e29f